A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes

Part of paid clinical trials in Little Rock, Arkansas.

Sponsor
Novo Nordisk A/S
Study ID
NCT07357740
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 64 Years
Healthy Volunteers
Not accepted

Interventions

  • CagriSema — DRUG
    Cagrilintide and Semaglutide will be administered subcutaneously using device 1 or device 2.
  • Placebo CagriSema — DRUG
    Placebo matched to Cagrilintide and Placebo matched to Semaglutide will be administered subcutaneously using device 1 or device 2.

Study Details

This study is being done to look at how well a study medicine called CagriSema helps people with diabetes lower their blood sugar. In this study the sponsor will compare two version of CagriSema injected by two different types of injection devices. Which treatment participants get is decided by chance. CagriSema is still being tested in studies and is not yet available for doctors to prescribe. The study will last for about 38 weeks.

Key Dates

Start date
Aug 27, 2026
Status verified
Mar 2026
Primary completion
Aug 25, 2027
Completion
Oct 13, 2027

Study Design

Enrollment
400 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: CagriSema in device 1 + Placebo CagriSema B in device 2
    Participants will receive CagriSema in device 1 followed by placebo matched to CagriSema B in device 2 subcutaneously once weekly in a dose escalation manner.
  • Experimental: CagriSema B in device 2 + Placebo CagriSema in device 1
    Participants will receive CagriSema B in device 2 followed by placebo matched to CagriSema in device 1 subcutaneously once weekly in a dose escalation manner.

Primary Outcome Measure

Change in glycated haemoglobin (HbA1c) [ Time Frame: Baseline to week 28 ]

Central Contacts

Locations (21)

FacilityCityStateZIPSite coordinators
Arkansas Clinical ResearchLittle RockArkansas72205-
Paradigm Clinical ResearchSan DiegoCalifornia92108-
Encompass Clinical Research_Spring ValleySpring ValleyCalifornia91978-
Diablo Clinical Research, Inc.Walnut CreekCalifornia94598-
Future Medical ResearchLongwoodFlorida32750-
Clinical Site Partners Kendall Flourish ResearchMiamiFlorida33186-
New Horizon Research CenterMiamiFlorida33165-
West Orange EndocrinologyOcoeeFlorida34761-
American Research Centers of FloridaPembroke PinesFlorida33027-
Center for Diab,Obes & MetabPembroke PinesFlorida33024-
Hope Clin Res & WellnessConyersGeorgia30094-
Elevate Clinical ResearchGurneeIllinois60031-
Accellacare of Duly Oak LawnOak LawnIllinois60453-
KDCILM, LLC & Accellacare US, Inc.WilmingtonNorth Carolina28401-
Advanced Medical Research - MaumeeMaumeeOhio43537-
Clinical Res CollaborativeCumberlandRhode Island02864-
Clinical Research AssociatesNashvilleTennessee37203-
The Endocrine CenterHoustonTexas77079-
Radiance Clinical ResearchLampasasTexas76550-
Quality Research IncSan AntonioTexas78209-
Medrasa Clinical ResearchShermanTexas75092-

Find similar trials in Little Rock, AR

By condition
Type 2 diabetes
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
Arkansas Clinical Research· Little Rock, ARParadigm Clinical Research· San Diego, CAEncompass Clinical Research_Spring Valley· Spring Valley, CADiablo Clinical Research, Inc.· Walnut Creek, CAFuture Medical Research· Longwood, FLClinical Site Partners Kendall Flourish Research· Miami, FL

Related Studies